彩色多普勒超声评分系统在卵巢良恶性肿块鉴别诊断中的应用
|
摘要
目的探讨彩色多普勒超声评分系统在卵巢良恶性肿块鉴别诊断中的临床应用价值。方法选择镇巴县中医院2015年1月至2018年2月收治的卵巢肿瘤患者180例,根据病理结果分为良性肿瘤组90例,恶性肿瘤组90例,比较两组患者Alaczar超声评分、搏动指数(PI)值、阻力指数(RI)值,根据病理诊断金标准分析Alaczar超声评分的灵敏度、准确率、特异度、阳性预测值、阴性预测值,比较恶性卵巢肿瘤不同临床分期Alaczar超声评分。结果恶性肿瘤组患者的Alaczar超声评分为(7.84±2.11)分,显著高于良性肿瘤组的(3.38±1.52)分,差异具有统计学意义(P<0.05),恶性肿瘤组PI值与RI值分别为(0.62±0.11)与(0.38±0.11),显著低于良性肿瘤组的(1.35±0.98)与(0.69±0.27),差异具有统计学意义(P<0.05);Alaczar超声评分系统诊断卵巢良恶性肿瘤灵敏度为88.5%,准确率为91.1%、特异度为94.0%、阳性预测值为94.4%、阴性预测值为87.8%;恶性卵巢肿瘤不同临床分期Alaczar超声评分[(5.2±1.09)分vs (5.4±1.07)分],差异无统计学意义(P>0.05)。结论 Alaczar超声评分系统可用于鉴别诊断卵巢肿瘤良恶性,具有较高的灵敏度、特异度、准确性。
Objective To discuss the application of Alaczar scoring system in the diagnosis of benign and malignant ovarian tumor. Methods A total of 180 patients with ovarian tumors admitted to Zhenba Hospital of Traditional Chinese Medicine from January 2015 to February 2018 were divided into benign tumor group(90 cases) and malignant tumor group(90 cases) according to pathological findings. Alaczar ultrasound score, pulsatility index(PI), and resistance index(RI) were compared between the two groups. The sensitivity, accuracy, specificity, positive predictive value, and negative predictive value of Alaczar ultrasound score were analyzed according to the gold standard of pathological diagnosis. Alaczar ultrasound score in different clinical stages of malignant ovarian tumors was compared. Results The Alaczar score of malignant tumor group was 7.84±2.11, significantly higher than 3.38±1.52 in benign tumor group(P<0.05). The PI value and RI value were 0.62±0.11 and 0.38±0.11 in malignant tumor group, significantly lower than 1.35±0.98 and 0.69±0.27 in benign tumor group(P<0.05). The sensitivity of Alaczar scoring system in the diagnosis of benign and malignant ovarian tumor was 88.5%, with the accuracy rate of 91.1%, the specificity of 94.0%, the positive predictive value of 94.4%, the negative predictive value of 87.8%. There was no significant difference in Alaczar score between different stages of malignant ovarian tumors:(5.2±1.09) vs(5.4±1.07), P>0.05. Conclusion Alaczar scoring system can be used to differentiate benign and malignant ovarian tumors, with high sensitivity, specificity and accuracy.
Objective To discuss the application of Alaczar scoring system in the diagnosis of benign and malignant ovarian tumor. Methods A total of 180 patients with ovarian tumors admitted to Zhenba Hospital of Traditional Chinese Medicine from January 2015 to February 2018 were divided into benign tumor group(90 cases) and malignant tumor group(90 cases) according to pathological findings. Alaczar ultrasound score, pulsatility index(PI), and resistance index(RI) were compared between the two groups. The sensitivity, accuracy, specificity, positive predictive value, and negative predictive value of Alaczar ultrasound score were analyzed according to the gold standard of pathological diagnosis. Alaczar ultrasound score in different clinical stages of malignant ovarian tumors was compared. Results The Alaczar score of malignant tumor group was 7.84±2.11, significantly higher than 3.38±1.52 in benign tumor group(P<0.05). The PI value and RI value were 0.62±0.11 and 0.38±0.11 in malignant tumor group, significantly lower than 1.35±0.98 and 0.69±0.27 in benign tumor group(P<0.05). The sensitivity of Alaczar scoring system in the diagnosis of benign and malignant ovarian tumor was 88.5%, with the accuracy rate of 91.1%, the specificity of 94.0%, the positive predictive value of 94.4%, the negative predictive value of 87.8%. There was no significant difference in Alaczar score between different stages of malignant ovarian tumors:(5.2±1.09) vs(5.4±1.07), P>0.05. Conclusion Alaczar scoring system can be used to differentiate benign and malignant ovarian tumors, with high sensitivity, specificity and accuracy.
引文
[1]冯桂婷,王莹,徐玥,等.彩色多普勒超声血流阻力指数联合血清CA125测定在卵巢肿瘤诊断中的应用价值[J].海南医学, 2017, 28(20):3346-3348.
[2]吴磊,郭娟,杜恩辅,等.超声造影诊断卵巢肿瘤价值的Meta分析[J].海南医学, 2015, 2(22):3387-3390.
[3]黄飞雪,白华,杨水华,等.超声诊断卵巢肿瘤良恶性的进展[J].广西医学, 2014, 28(12):1775-1777.
[4]李斯琴.彩色多普勒超声引导下活检结合造影在卵巢肿瘤诊断中的应用价值[J].临床和实验医学杂志, 2014, 13(5):389-390.
[5]陈铃,杨戈文,石小红.彩色多普勒超声评分系统诊断卵巢良恶性肿块的价值[J].广东医学, 2012, 33(20):3070-3071.
[6]刘翔宇,王义成.卵巢肿瘤的彩色多普勒超声诊断进展[J].河北医药, 2013, 35(4):59-60.
[7] ALCDZAR JL, MERCE LT, LAPARTE C, et al. A new scoring system to differentiate benign from malignant adnexal masses[J]. Am J Obstet Gynecol, 2003, 188(3):685-692.
[8]王颖.彩色多普勒超声与二维超声在鉴别诊断卵巢良恶性肿瘤对照研究[J].中国现代医学杂志, 2013, 23(22):85-86.
[9] TIMMERMAN D, VALENTIN L, BOURNE T H, et al. Terms deftnitions and measurements to describe the sonographic features of adnexal tumors:a consensus opinion from the International Ovarian Tumor Analysis(IOTA)Group[J]. Ultrasound Obstet Gynecol, 2000, 16(5):500-505.
[10] ALCDZAR J L, ROYO P, JURADO M, et al. Triage for surgical management of ovarian tumors in asymptomatic women:assessment of an ultrasound based scoring system[J]. Ultrasound Obstet Gynecol, 2008, 32(2):220-225.
[11] MAJEED H, RAMZAN A, IMRAN F, et al. Validity of resistive index for the diagnosis of malignant ovarian masses[J]. J Pak Med Assoc, 2011, 61(11):1104-1107.
[12]黄瑞英.血清CEA, AFP, CA125和CA199联合检测对卵巢癌的诊断价值[J].广西医学, 2011, 33(3):310-311.
[2]吴磊,郭娟,杜恩辅,等.超声造影诊断卵巢肿瘤价值的Meta分析[J].海南医学, 2015, 2(22):3387-3390.
[3]黄飞雪,白华,杨水华,等.超声诊断卵巢肿瘤良恶性的进展[J].广西医学, 2014, 28(12):1775-1777.
[4]李斯琴.彩色多普勒超声引导下活检结合造影在卵巢肿瘤诊断中的应用价值[J].临床和实验医学杂志, 2014, 13(5):389-390.
[5]陈铃,杨戈文,石小红.彩色多普勒超声评分系统诊断卵巢良恶性肿块的价值[J].广东医学, 2012, 33(20):3070-3071.
[6]刘翔宇,王义成.卵巢肿瘤的彩色多普勒超声诊断进展[J].河北医药, 2013, 35(4):59-60.
[7] ALCDZAR JL, MERCE LT, LAPARTE C, et al. A new scoring system to differentiate benign from malignant adnexal masses[J]. Am J Obstet Gynecol, 2003, 188(3):685-692.
[8]王颖.彩色多普勒超声与二维超声在鉴别诊断卵巢良恶性肿瘤对照研究[J].中国现代医学杂志, 2013, 23(22):85-86.
[9] TIMMERMAN D, VALENTIN L, BOURNE T H, et al. Terms deftnitions and measurements to describe the sonographic features of adnexal tumors:a consensus opinion from the International Ovarian Tumor Analysis(IOTA)Group[J]. Ultrasound Obstet Gynecol, 2000, 16(5):500-505.
[10] ALCDZAR J L, ROYO P, JURADO M, et al. Triage for surgical management of ovarian tumors in asymptomatic women:assessment of an ultrasound based scoring system[J]. Ultrasound Obstet Gynecol, 2008, 32(2):220-225.
[11] MAJEED H, RAMZAN A, IMRAN F, et al. Validity of resistive index for the diagnosis of malignant ovarian masses[J]. J Pak Med Assoc, 2011, 61(11):1104-1107.
[12]黄瑞英.血清CEA, AFP, CA125和CA199联合检测对卵巢癌的诊断价值[J].广西医学, 2011, 33(3):310-311.